A DIFFERENTIATED APPROACH TO THE PREVENTION OF OBESITY-ASSOCIATED METABOLIC SYNDROME IN PATIENTS WITH PSORIASIS: A LITERATURE REVIEW AND A PROPOSED ALGORITHM
https://doi.org/10.64854/2790-1289-2026-53-3-12
Abstract
Relevance. Metabolic syndrome is more common in patients with psoriasis than in people without psoriasis, with more than twice the odds. Their coexistence is associated with increased cardiovascular risk and requires comprehensive prevention.
Objective. To summarise current evidence on pathogenetic mechanisms, risk stratification tools and preventive interventions in obesity-associated metabolic syndrome in psoriasis, and to present the differentiated prevention algorithm we have developed.
Materials and Methods. A narrative review considered publications from 2015–2026 identified in PubMed/MEDLINE, Scopus, Web of Science, Cochrane Library, eLibrary and Google Scholar. Sources included systematic and narrative reviews, meta-analyses, interventional and observational studies, Mendelian randomisation studies and clinical guidelines, together with the authors’ previously published research.
Results. The association between psoriasis and metabolic disturbances is bidirectional; shared mechanisms include systemic inflammation, insulin resistance, adipokine imbalance and endothelial dysfunction. Mendelian randomisation studies support a causal effect of higher body mass index on psoriasis risk. In a meta-analysis of six randomised trials, weight reduction through diet or physical activity was associated with a mean PASI reduction of 2.59 points relative to controls. Based on the review and the authors’ research, an algorithm is proposed for patients with psoriasis and body mass index above 28 kg/ m². A preliminary integral screening index defines three categories for the proposed intensity of preventive care; immunological and genetic assessments are considered research components.
Conclusions. The proposed algorithm organises preventive measures and directions for further research into personalised care in psoriasis. Its ability to predict metabolic syndrome, clinical effectiveness and the value of additional assessments require prospective evaluation in an independent cohort.
About the Authors
B. A. ZhumabekovaKazakhstan
Zhumabekova Botagoz – PhD student
Almaty
G. K. Askarova
Kazakhstan
Askarova Gulsum – Doctor of Medical Sciences, Professor, Head of the Course of Dermatovenereology
Almaty
Zh. A. Akanov
Kazakhstan
Akanov Zhanay – Candidate of Medical Sciences, President of the Public Foundation «Kazakhstan Society for the Study of Diabetes»
Almaty
G. S. Svyatova
Kazakhstan
Svyatova Gulnara – Doctor of Medical Sciences, Professor, Head of the Research and Education Department at «Center for Molecular Medicine» LLP
Almaty
U. A. Zhumabekova
Kazakhstan
Zhumabekova Ulzhan – junior doctor
Almaty
A. A. Zhumabekov
Kazakhstan
Zhumabekov Almukhamet – 4th-year student
Almaty
References
1. Parisi R., Iskandar I. Y. K., Kontopantelis E. et al. (2020). National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. British Medical Journal, 369, m1590. DOI: 10.1136/bmj.m1590.
2. Global report on psoriasis. (2016). Geneva: World Health Organization, 48, from: https://www.who.int/publications/i/item/9789241565189.
3. Griffiths C. E. M., Armstrong A. W., Gudjonsson J. E., Barker J. N. W. N. (2021). Psoriasis. Lancet, 397(10281), 1301–1315. DOI: 10.1016/S0140-6736(20)32549-6.
4. Boehncke W. H., Schön M. P. (2015). Psoriasis. Lancet, 386(9997), 983–994. DOI: 10.1016/S0140-6736(14)61909-7.
5. Takeshita J., Grewal S., Langan S. M. et al. (2017). Psoriasis and comorbid diseases: epidemiology. Journal of the American Academy of Dermatology, 76(3), 377–390. DOI: 10.1016/j.jaad.2016.07.064.
6. Gisondi P., Fostini A. C., Fossà I., Girolomoni G., Targher G. (2018). Psoriasis and the metabolic syndrome. Clinics in Dermatology, 36(1), 21–28. DOI: 10.1016/j.clindermatol.2017.09.005.
7. Singh S., Young P. M., Armstrong A. W. (2017). An update on psoriasis and metabolic syndrome: a meta-analysis of observational studies. PLoS ONE, 12(7), e0181039. DOI: 10.1371/journal.pone.0181039.
8. Rodríguez-Zúñiga M. J. M., García-Perdomo H. A. (2017). Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome. Journal of the American Academy of Dermatology, 77(4), 657–666. DOI: 10.1016/j.jaad.2017.04.1133.
9. Alajroush W. A., Alrshid A. I., Alajlan A. H. et al. (2024). Psoriasis and metabolic disorders: a comprehensive meta-analysis of million adults worldwide. Cureus, 16.(1), e52099. DOI: 10.7759/cureus.52099.
10. Zhumabekova B. A., Askarova G. K., Akanov Zh. A., Islamov E. N., Mojynbaeva Sh. M. (2025). Rol' ozhirenija v patogeneze psoriaza i metabolicheskogo sindroma. Obzor literatury. Ftiziopul'monologija, 47(1), 6–12. DOI: 10.26212/2227-1937.2025.87.84.001. (In Russian).
11. Snekvik I., Smith C. H., Nilsen T. I. L. et al. (2017). Obesity, waist circumference, weight change, and risk of incident psoriasis: prospective data from the HUNT Study. Journal of Investigative Dermatology, 137(12), 2484–2490. DOI: 10.1016/j.jid.2017.07.822.
12. Budu-Aggrey A., Brumpton B., Tyrrell J. et al. (2019). Evidence of a causal relationship between body mass index and psoriasis: a Mendelian randomization study. PLoS Medicine, 16(1), e1002739. DOI: 10.1371/journal.pmed.1002739.
13. Ogawa K., Stuart P. E., Tsoi L. C. et al. (2019). A transethnic Mendelian randomization study identifies causality of obesity on risk of psoriasis. Journal of Investigative Dermatology, 139(6), 1397–1400. DOI: 10.1016/j.jid.2018.11.023.
14. Zhumabekova B., Svyatova G., Askarova G. et al. (2026). Metabolic and candidate genetic factors associated with overweight/obesity in patients of Kazakh ethnicity with psoriasis: a cross-sectional study. Medicina, 62(8), 1448. DOI: 10.3390/medicina62081448.
15. Elmets C. A., Leonardi C. L., Davis D. M. R. et al. (2019). Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. Journal of the American Academy of Dermatology, 80(4), 1073–1113. DOI: 10.1016/j.jaad.2018.11.058.
16. Visseren F. L. J., Mach F., Smulders Y. M. et al. (2021). ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 42(34), 3227–3337. DOI: 10.1093/eurheartj/ehab484.
17. Zhumabekova B. A., Askarova G. K., Akanov Zh. A., Kamhen V. B., Baltabaev M. K. (2026). Ozhirenie-associirovannyj metabolicheskij risk u pacientov s psoriazom: ROC-analiz kliniko-laboratornyh pokazatelej i integral'nyj skriningovyj indeks. Vestnik KazNMU, 2 (77), 53–67. DOI: 10.53065/kaznmu.2026.77.2.004. (In Russian).
18. Wu J. J., Kavanaugh A., Lebwohl M. G., Gniadecki R., Merola J. F. (2022). Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. Journal of the European Academy of Dermatology and Venereology, 36(6), 797–806. DOI: 10.1111/jdv.18044.
19. Yamazaki F. (2021). Psoriasis: comorbidities. The Journal of Dermatology, 48(6), 732–740. DOI: 10.1111/1346-8138.15840.
20. Miao C., Li J., Li Y., Zhang X. (2019). Obesity and dyslipidemia in patients with psoriasis: a case-control study. Medicine, 98(31), e16323. DOI: 10.1097/MD.0000000000016323.
21. Nowowiejska J., Baran A., Flisiak I. (2020). Psoriasis and cardiometabolic disorders. Dermatology Review/Przegląd Dermatologiczny, 107(6), 508–520. DOI: 10.5114/DR.2020.103887.
22. Snekvik I., Nilsen T. I. L., Romundstad P. R., Saunes M. (2019). Metabolic syndrome and risk of incident psoriasis: prospective data from the HUNT Study, Norway. British journal of dermatology, 180(1), 94–99. DOI: 10.1111/bjd.16885.
23. Candia R., Ruiz A., Torres-Robles R. et al. (2015). Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis. Journal of the European Academy of Dermatology and Venereology, 29(4), 656–662. DOI: 10.1111/jdv.12847.
24. Ojnotkinova O. Sh., Rojtberg G. E., Sharhun O. O., Shaposhnikova O. A. (2024). Serdechno-sosudistyj risk u komorbidnyh pacientov s psoriazom i metabolicheskim sindromom. Jeffektivnaja farmakoterapija, 20(43), 70–76. DOI: 10.33978/2307-3586-2024-20-43-70-76. (In Russian).
25. Ufimceva M. A., Popov A. A., Fedotova L. V., Myl'nikova E. S., Bochkarev Ju. M., Zhunisova D. S. (2020). Psoriaz i metabolicheskij sindrom: obzor literatury. Ozhirenie i metabolizm, 17(4), 369–374. DOI: 10.14341/omet12517. (In Russian).
26. Hao Y., Zhu Y., Zou S. et al. (2021). Metabolic syndrome and psoriasis: mechanisms and future directions. Frontiers in Immunology, 12, 711060. DOI: 10.3389/fimmu.2021.711060.
27. Secchiero P., Rimondi E., Marcuzzi A. et al. (2024). Metabolic syndrome and psoriasis: pivotal roles of chronic inflammation and gut microbiota. International Journal of Molecular Sciences, 25(15), 8098. DOI: 10.3390/ijms25158098.
28. Bai F., Zheng W., Dong Y. et al. (2018). Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis. Oncotarget, 9(1), 1266–1278. DOI: 10.18632/oncotarget.22260.
29. Cataldi C., Mari N. L., Lozovoy M. A. B. et al. (2019). Proinflammatory and anti-inflammatory cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors. Inflammation Research, 68(7), 557–567. DOI: 10.1007/s00011-019-01238-8.
30. Wolk K., Sabat R. (2016). Adipokines in psoriasis: an important link between skin inflammation and metabolic alterations. Reviews in endocrine & metabolic disorders, 17(3), 305–317. DOI: 10.1007/s11154-016-9381-0.
31. Ruiyang B., Panayi A., Ruifang W., Peng Z., Siqi F. (2021). Adiponectin in psoriasis and its comorbidities: a review. Lipids in Health and Disease, 20, 87. DOI: 10.1186/s12944-021-01510-z.
32. Wong Y., Nakamizo S., Tan K. J., Kabashima K. (2019). An update on the role of adipose tissues in psoriasis. Frontiers in Immunology, 10, 1507. DOI: 10.3389/fimmu.2019.01507.
33. Pankiv I. V. (2021). Insulin resistance in patients with psoriasis. International Journal of Endocrinology, 17(7), 570–574. DOI: 10.22141/2224-0721.17.7.2021.244973.
34. Jensen P., Skov L. (2016), Psoriasis and obesity. Dermatology, 232(6), 633–639. DOI: 10.1159/000455840.
35. Jensen P., Christensen R., Zachariae C. et al. (2016). Long-term effects of weight reduction on the severity of psoriasis in a cohort derived from a randomized trial: a prospective observational follow-up study. The American journal of clinical nutrition, 104(2), 259–265. DOI: 10.3945/ajcn.115.125849.
36. Upala S., Sanguankeo A. (2015). Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta-analysis. International Journal of Obesity, 39(8), 1197–1202. DOI: 10.1038/ijo.2015.64.
37. Mahil S. K., McSweeney S. M., Kloczko E. et al. (2019). Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A critically appraised topic. British journal of dermatology, 181(5), 946–953. DOI: 10.1111/bjd.17741.
38. Ford A. R., Siegel M., Bagel J. et al. (2018). Dietary recommendations for adults with psoriasis or psoriatic arthritis from the Medical Board of the National Psoriasis Foundation: a systematic review. JAMA Dermatology, 154(8), 934–950. DOI: 10.1001/jamadermatol.2018.1412.
39. Phan C., Touvier M., Kesse-Guyot E. et al. (2018). Association between Mediterranean anti-inflammatory dietary profile and severity of psoriasis: results from the NutriNet-Santé cohort. JAMA Dermatology, 154(9), 1017–1024. DOI: 10.1001/jamadermatol.2018.2127.
40. Castaldo G., Rastrelli L., Galdo G. et al. (2020). Aggressive weight-loss program with a ketogenic induction phase for the treatment of chronic plaque psoriasis: a proof-of-concept, single-arm, open-label clinical trial. Nutrition, 74, 110757. DOI: 10.1016/j.nut.2020.110757.
41. Barrea L., Balato N., Di Somma C. et al. (2015). Nutrition and psoriasis: is there any association between the severity of the disease and adherence to the Mediterranean diet?. Journal of Translational Medicine, 13, 18. DOI: 10.1186/s12967-014-0372-1.
42. Gelfand J. M., Shin D. B., Duffin K. C. (2020). et al. A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-S). Journal of Investigative Dermatology, 140(9), 1784–1793. DOI: 10.1016/j.jid.2020.01.025.
43. Gelfand J. M., Shin D. B., Alavi A. et al. (2020). A phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U trial). Journal of Investigative Dermatology, 140(1), 85–93. DOI: 10.1016/j.jid.2019.07.679.
44. Rungapiromnan W., Yiu Z. Z. N., Warren R. B. et al. (2017). Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. British journal of dermatology, 176(4), 890–901. DOI: 10.1111/bjd.14964.
45. Olisova O. Ju., Anpilogova E. M. (2020). Sistemnaja terapija psoriaza: ot metotreksata do genno-inzhenernyh biologicheskih preparatov. Vestnik dermatologii i venerologii, 96(3), 7–26. DOI: 10.25208/vdv1162. (In Russian).
46. Nicolau J., Nadal A., Sanchís P. et al. (2026). Dermatological and metabolic benefits of semaglutide in psoriasis with obesity: a 6-month prospective cohort study. Clinical & Experimental Dermatology, 51(3), 442–450. DOI: 10.1093/ced/llaf473.
47. Bellinato F., Maurelli M., Geat D., Girolomoni G., Gisondi P. (2024). Managing the patient with psoriasis and metabolic comorbidities. American Journal of Clinical Dermatology, 25(4), 527–540. DOI: 10.1007/s40257-024-00857-0.
48. Qi Q., Downer M. K., Kilpeläinen T. O. et al. (2015). Dietary intake, FTO genetic variants, and adiposity: a combined analysis of over 16 000 children and adolescents. Diabetes, 64(7), 2467–2476. DOI: 10.2337/db14-1629.
49. Czarnecka A., Purzycka-Bohdan D., Zabłotna M. et al. (2024). Analysis of clinical and genetic factors of obesity and psoriasis concomitance — the influence of body mass composition, prevalence of mood disorders, environmental factors and FTO gene polymorphisms (rs9939609, rs1558902). Biomedicines, 12(3), 517. DOI: 10.3390/biomedicines12030517.
50. Tupikowska-Marzec M., Kolačkov K., Zdrojowy-Wełna A. et al. (2019). The influence of FTO polymorphism rs9939609 on obesity, some clinical features, and disturbance of carbohydrate metabolism in patients with psoriasis. BioMed Research International, 2019, 7304345. DOI: 10.1155/2019/7304345.
51. Kisielnicka A., Sobalska-Kwapis M., Purzycka-Bohdan D. et al. (2022). The analysis of a genome-wide association study (GWAS) of overweight and obesity in psoriasis. International Journal of Molecular Sciences, 23(13), 7396. DOI: 10.3390/ijms23137396.
52. Zhumabekova B. A., Askarova G. K., Akanov Zh. A., Svjatova G. S. (2026). Algoritm profilaktiki metabolicheskogo sindroma, associirovannogo s ozhireniem, u pacientov s psoriazom: svidetel'stvo o vnesenii svedenij v gosudarstvennyj reestr prav na ob#ekty, ohranjaemye avtorskim pravom, №76743 ot 21.07.2026. Ministerstvo justicii Respubliki Kazahstan. Almaty. (In Russian).
53. Collins G. S., Reitsma J. B., Altman D. G., Moons K. G. M. (2015). Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Annals of Internal Medicine, 162(1), 55–63. DOI: 10.7326/M14-0697.
Review
For citations:
Zhumabekova B.A., Askarova G.K., Akanov Zh.A., Svyatova G.S., Zhumabekova U.A., Zhumabekov A.A. A DIFFERENTIATED APPROACH TO THE PREVENTION OF OBESITY-ASSOCIATED METABOLIC SYNDROME IN PATIENTS WITH PSORIASIS: A LITERATURE REVIEW AND A PROPOSED ALGORITHM. Actual Problems of Theoretical and Clinical Medicine. 2026;(3):189-208. (In Russ.) https://doi.org/10.64854/2790-1289-2026-53-3-12
JATS XML
